(Stroke. 2000;31:1686.)
© 2000 American Heart Association, Inc.
Original Contributions |
Proteasome Inhibitor PS519 Reduces Infarction and Attenuates Leukocyte Infiltration in a Rat Model of Focal Cerebral Ischemia
From Walter Reed Army Institute of Research, Division of Neurosciences, Washington, DC (J.B.P., A.J.W., F.C.T.); the National Research Council, Research Assoc Program, Washington, DC (J.B.P.); and ProScript, Inc, Cambridge, Mass (J.A., P.J.E.).
Correspondence to Frank C. Tortella, Walter Reed Army Institute of Research, Division of Neurosciences, Bldg 503, Forest Glen Annex, Silver Spring, MD 20910. E-mail frank.tortella{at}na.amedd.army.mil
Background and
Purpose—Reperfusion brain injury after cerebral ischemia
is associated with a developing inflammatory response at the site of
infarction. Proteasome inhibitors block nuclear factor-
B
activation and provide anti-inflammatory effects in several animal
models of peripheral inflammation. We tested the novel
proteasome inhibitor PS519 in a rat model of transient
focal ischemia to establish its pharmacodynamics as a
neuroprotection treatment and related effects on leukocyte
infiltration.
Methods—Rats were subjected to 2 hours of focal cerebral ischemia by means of the filament method of middle cerebral artery occlusion (MCAo). After either 22 or 70 hours of reperfusion, infarct size was measured and neurological function, electroencephalographic (EEG) activity, and/or neutrophil and macrophage infiltration was quantified. PS519 was administered in a single intravenous bolus at 2 hours after MCAo. In addition, the therapeutic window for PS519 was estimated by delaying treatment for 4 or 6 hours after MCAo.
Results—Dose-response analysis of infarct volume at 24 hours revealed that PS519 neuroprotection approached 60%, and clinical evaluations showed significant improvements in neurological function and EEG activity. Neutrophil infiltration at 24 hours was also significantly decreased in cortical and striatal infarcted tissue of PS519-treated rats. Delaying the PS519 treatment up to 4 hours continued to result in significant neuroprotection. In the 72-hour injury model, infarction was reduced 40% by PS519, and significant improvements in neurological function and EEG recovery were again measured. Considerable reductions in both neutrophil and macrophage infiltration were evident.
Conclusions—PS519 mitigates infarction and improves neurological recovery in brain-injured rats, an effect in part caused by a reduction in the leukocyte inflammatory response.
Editorial Comment
Neuroscience Research, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana
This article has been cited by other articles:
 |
|
 |
|
  K. Liu, S. Mori, H. K. Takahashi, Y. Tomono, H. Wake, T. Kanke, Y. Sato, N. Hiraga, N. Adachi, T. Yoshino, et al. Anti-high mobility group box 1 monoclonal antibody ameliorates brain infarction induced by transient ischemia in rats FASEB J, December 1, 2007; 21(14): 3904 - 3916. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. C. Moss, W. E. Stansfield, M. S. Willis, R.-H. Tang, and C. H. Selzman IKKbeta inhibition attenuates myocardial injury and dysfunction following acute ischemia-reperfusion injury Am J Physiol Heart Circ Physiol, October 1, 2007; 293(4): H2248 - H2253. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Yamamoto, H. Sawada, Y. Izumi, T. Kume, H. Katsuki, S. Shimohama, and A. Akaike Proteasome Inhibition Induces Glutathione Synthesis and Protects Cells from Oxidative Stress: RELEVANCE TO PARKINSON DISEASE J. Biol. Chem., February 16, 2007; 282(7): 4364 - 4372. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Henninger, K. M. Sicard, K. F. Schmidt, J. Bardutzky, and M. Fisher Comparison of Ischemic Lesion Evolution in Embolic Versus Mechanical Middle Cerebral Artery Occlusion in Sprague Dawley Rats Using Diffusion and Perfusion Imaging Stroke, May 1, 2006; 37(5): 1283 - 1287. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Wojcik and M. Di Napoli Ubiquitin-Proteasome System and Proteasome Inhibition: New Strategies in Stroke Therapy Stroke, June 1, 2004; 35(6): 1506 - 1518. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Williams, R. Berti, J. R. Dave, P. J. Elliot, J. Adams, and F. C. Tortella Delayed Treatment of Ischemia/Reperfusion Brain Injury: Extended Therapeutic Window with the Proteosome Inhibitor MLN519 Stroke, May 1, 2004; 35(5): 1186 - 1191. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Gan, S. Ye, A. Chu, K. Anton, S. Yi, V. A. Vincent, D. von Schack, D. Chin, J. Murray, S. Lohr, et al. Identification of Cathepsin B as a Mediator of Neuronal Death Induced by A{beta}-activated Microglial Cells Using a Functional Genomics Approach J. Biol. Chem., February 13, 2004; 279(7): 5565 - 5572. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Glickman and A. Ciechanover The Ubiquitin-Proteasome Proteolytic Pathway: Destruction for the Sake of Construction Physiol Rev, April 1, 2002; 82(2): 373 - 428. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Hayashi and D. L. Faustman Development of Spontaneous Uterine Tumors in Low Molecular Mass Polypeptide-2 Knockout Mice Cancer Res., January 1, 2002; 62(1): 24 - 27. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Zhang, Z. G. Zhang, R. L. Zhang, M. Lu, J. Adams, P. J. Elliott, and M. Chopp Postischemic (6-Hour) Treatment With Recombinant Human Tissue Plasminogen Activator and Proteasome Inhibitor PS-519 Reduces Infarction in a Rat Model of Embolic Focal Cerebral Ischemia Stroke, December 1, 2001; 32(12): 2926 - 2931. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Matilla, C. Gorbea, D. D. Einum, J. Townsend, A. Michalik, C. van Broeckhoven, C. C. Jensen, K. J. Murphy, L. J. Ptacek, and Y.-H. Fu Association of ataxin-7 with the proteasome subunit S4 of the 19S regulatory complex Hum. Mol. Genet., November 1, 2001; 10(24): 2821 - 2831. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Williams, X. M. Lu, B. Slusher, and F. C. Tortella Electroencephalogram Analysis and Neuroprotective Profile of the N-Acetylated-alpha -Linked Acidic Dipeptidase Inhibitor, GPI5232, in Normal and Brain-Injured Rats J. Pharmacol. Exp. Ther., October 1, 2001; 299(1): 48 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Itoh, M. Takaoka, A. Shibata, M. Ohkita, and Y. Matsumura Preventive Effect of Lactacystin, a Selective Proteasome Inhibitor, on Ischemic Acute Renal Failure in Rats J. Pharmacol. Exp. Ther., August 1, 2001; 298(2): 501 - 507. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Yin, G. Laevsky, and C. Giardina Butyrate Suppression of Colonocyte NF-kappa B Activation and Cellular Proteasome Activity J. Biol. Chem., November 21, 2001; 276(48): 44641 - 44646. [Abstract] [Full Text] [PDF]
|
|